GCC Non Invasive Prenatal Testing Market

ID: MRFR/MED/49126-HCR
200 Pages
Nidhi Mandole
Last Updated: April 06, 2026
GCC Non-Invasive Prenatal Testing Market Research Report: Size, Share, Trend Analysis By Test Type (Cell-Free DNA Testing, Biochemical Testing, Combined Screening), By Applications (Fetal Gender Determination, Chromosomal Abnormalities Screening, Rhesus Disease Screening), By Technology (Next Generation Sequencing, Microarray Analysis, Polymerase Chain Reaction) and By End Users (Hospitals, Diagnostic Laboratories, Direct-to-Consumer Companies) - Growth Outlook & Industry Forecast 2025 To 2035
GCC Non Invasive Prenatal Testing Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)10.76%
2024 Market Size$ 45.5 Million
2025 Market Size$ 50.4 Million
2035 Market Size$ 140 Million
Key Players
Illumina
Roche
Natera
Fulgent Genetics
LabCorp
Quest Diagnostics
Opportunities
  • Increasing Healthcare Expenditure
  • Government Initiatives and Policies
  • Rising Birth Rates and Maternal Age
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Chemicals and Materials, BY Test Type (USD Million)
      1. 4.1.1 Cell-Free Fetal DNA Testing
      2. 4.1.2 Biochemical Markers Testing
      3. 4.1.3 Ultrasound Screening
    2. 4.2 Chemicals and Materials, BY Application (USD Million)
      1. 4.2.1 Trisomy Detection
      2. 4.2.2 Single Gene Disorders
      3. 4.2.3 Sex Chromosome Abnormalities
    3. 4.3 Chemicals and Materials, BY Technology (USD Million)
      1. 4.3.1 Next-Generation Sequencing
      2. 4.3.2 Microarray Analysis
      3. 4.3.3 Massively Parallel Sequencing
    4. 4.4 Chemicals and Materials, BY End User (USD Million)
      1. 4.4.1 Hospitals
      2. 4.4.2 Diagnostic Laboratories
      3. 4.4.3 Research Institutions
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Illumina (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Roche (CH)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Natera (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Fulgent Genetics (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 LabCorp (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Quest Diagnostics (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 HaploX (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Genomic Health (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 GCC MARKET ANALYSIS BY TEST TYPE
    3. 6.3 GCC MARKET ANALYSIS BY APPLICATION
    4. 6.4 GCC MARKET ANALYSIS BY TECHNOLOGY
    5. 6.5 GCC MARKET ANALYSIS BY END USER
    6. 6.6 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF CHEMICALS AND MATERIALS
    9. 6.9 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
    11. 6.11 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
    12. 6.12 CHEMICALS AND MATERIALS, BY TEST TYPE, 2024 (% SHARE)
    13. 6.13 CHEMICALS AND MATERIALS, BY TEST TYPE, 2024 TO 2035 (USD Million)
    14. 6.14 CHEMICALS AND MATERIALS, BY APPLICATION, 2024 (% SHARE)
    15. 6.15 CHEMICALS AND MATERIALS, BY APPLICATION, 2024 TO 2035 (USD Million)
    16. 6.16 CHEMICALS AND MATERIALS, BY TECHNOLOGY, 2024 (% SHARE)
    17. 6.17 CHEMICALS AND MATERIALS, BY TECHNOLOGY, 2024 TO 2035 (USD Million)
    18. 6.18 CHEMICALS AND MATERIALS, BY END USER, 2024 (% SHARE)
    19. 6.19 CHEMICALS AND MATERIALS, BY END USER, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 GCC MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TEST TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY APPLICATION, 2025-2035 (USD Million)
      3. 7.2.3 BY TECHNOLOGY, 2025-2035 (USD Million)
      4. 7.2.4 BY END USER, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

GCC Non Invasive Prenatal Testing Market Segmentation

GCC Non Invasive Prenatal Testing Market By Test Type (USD Million, 2025-2035)

  • Cell-Free Fetal DNA Testing
  • Biochemical Markers Testing
  • Ultrasound Screening

GCC Non Invasive Prenatal Testing Market By Application (USD Million, 2025-2035)

  • Trisomy Detection
  • Single Gene Disorders
  • Sex Chromosome Abnormalities

GCC Non Invasive Prenatal Testing Market By Technology (USD Million, 2025-2035)

  • Next-Generation Sequencing
  • Microarray Analysis
  • Massively Parallel Sequencing

GCC Non Invasive Prenatal Testing Market By End User (USD Million, 2025-2035)

  • Hospitals
  • Diagnostic Laboratories
  • Research Institutions
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.